Core Viewpoint - FibroBiologics, Inc. has successfully closed a registered direct offering, raising approximately $4 million through the issuance of common stock and pre-funded warrants, with a unique payment method involving gold coins [1][2][4]. Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 270 patents [1][10]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [10]. Offering Details - The company issued 3,540,000 shares of common stock and pre-funded warrants to purchase 8,570,203 shares at a price of $0.3303 per share [1]. - The purchase price was paid with sovereign-issued .9999 fine gold coins valued at $4,069.18 per ounce [2]. - In a concurrent private placement, unregistered warrants were issued to purchase up to 12,110,203 shares of common stock, with an exercise price of $0.3303 per share [3]. Financial Implications - The gross proceeds from the offering were approximately $4 million, intended for general corporate purposes, including debt satisfaction [4]. - If the unregistered warrants are fully exercised for cash following stockholder approval, the company could receive an additional $4 million [4]. Regulatory Compliance - The shares and pre-funded warrants were offered under a shelf registration statement previously filed with the SEC [5]. - The unregistered warrants were offered in a private placement and have not been registered under the Securities Act [6].